SecBot SecBot
SECBOTREPLAY Home › Report › HRTX

HRTX · Heron Therapeutics (HRTX) entered into a definitive asset purchase…

HERON THERAPEUTICS, INC. /DE/ · 8-K filed Nov 9, 2026 at 07:40 ET

At the news

NEUTRALIMPACT 6/10

8-K filed Nov 9, 2026 at 07:40 ET

Heron Therapeutics (HRTX) entered into a definitive asset purchase agreement to sell its commercial-stage anti-nausea and post-operative pain product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix Inc. (CRMD) for $145M in cash plus 14,583,333 CRMD shares, along with tiered royalty payments on CINVANTI/SUSTOL net sales above a $25M threshold and earn-out payments on ZYNRELEF up to $55M. Concurrently, Heron exchanged its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, effectively deleveraging its balance sheet. The transaction requires Heron stockholder approval and is expected to close within six months.

  • Heron sells its commercial product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix for $145M cash plus 14,583,333 CRMD shares (Stock Consideration).
  • Heron exchanges its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, eliminating that debt.
  • Heron is eligible for 5% royalty payments on CINVANTI/SUSTOL net sales above a $25M annual threshold for calendar years 2027-2029.
  • Heron is eligible for earn-out payments on ZYNRELEF: $25M if 2028 net sales reach $65M, plus $30M if they reach $95M (max $55M).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access